| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Adisorn Ratanaphan | |
| P2860 | cites work | The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage | Q22010200 |
| MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks | Q24299852 | ||
| RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins | Q24300411 | ||
| RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly | Q24300428 | ||
| Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response | Q24306765 | ||
| RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites | Q24306789 | ||
| Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response | Q24306807 | ||
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation | Q40930380 | ||
| BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). | Q41056489 | ||
| Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen | Q41160149 | ||
| Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens | Q41336813 | ||
| Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers | Q42448782 | ||
| Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction | Q42454067 | ||
| Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients | Q42468646 | ||
| BRCA1 dysfunction in sporadic basal-like breast cancer | Q42502209 | ||
| Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry | Q42510173 | ||
| The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs | Q42874055 | ||
| A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer | Q44613177 | ||
| Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein-protein and protein-DNA interactions? | Q45168174 | ||
| Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. | Q46121546 | ||
| The RING finger protein RNF8 recruits UBC13 for lysine 63-based self polyubiquitylation | Q46744819 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| DNA recognition by the oestrogen receptor: from solution to the crystal | Q47964761 | ||
| BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. | Q52537650 | ||
| Linking up and interacting with BRCT domains. | Q53357646 | ||
| Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. | Q53395804 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Transcriptional activation by BRCA1 | Q59072814 | ||
| Traffic Control for BRCA1 | Q59238339 | ||
| BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells | Q60568779 | ||
| Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors | Q64387467 | ||
| The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin | Q64388522 | ||
| Steroidal pure antioestrogens | Q68965435 | ||
| ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen | Q74199528 | ||
| The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators | Q74265958 | ||
| Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors | Q80695171 | ||
| Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients | Q81688258 | ||
| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells | Q37355031 | ||
| BRCA1 and implications for response to chemotherapy in ovarian cancer | Q37377021 | ||
| BRCA1 and its toolbox for the maintenance of genome integrity | Q37507563 | ||
| Triple-negative breast cancer: disease entity or title of convenience? | Q37793824 | ||
| Aromatase inhibitors and breast cancer prevention | Q37975542 | ||
| The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. | Q39762239 | ||
| Cisplatin-damaged BRCA1 exhibits altered thermostability and transcriptional transactivation | Q39875600 | ||
| Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. | Q40052411 | ||
| TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. | Q40453388 | ||
| Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation | Q40568772 | ||
| BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis | Q40626126 | ||
| The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | Q40657407 | ||
| Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway | Q40773708 | ||
| Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation | Q40798697 | ||
| Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells | Q40856707 | ||
| Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains | Q24645684 | ||
| Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase | Q24653776 | ||
| Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors | Q24800777 | ||
| The oestrogen receptor recognizes an imperfectly palindromic response element through an alternative side-chain conformation | Q27730214 | ||
| The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements | Q27731441 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation | Q28207617 | ||
| Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2 | Q28212708 | ||
| Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein | Q28214794 | ||
| Solution structure of the DNA-binding domain of the oestrogen receptor | Q28263533 | ||
| Basic guide to the mechanisms of antiestrogen action | Q28275149 | ||
| MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals | Q28292900 | ||
| Association of BRCA1 with Rad51 in mitotic and meiotic cells | Q28302118 | ||
| Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer | Q28372484 | ||
| Nuclear receptor coregulators: cellular and molecular biology | Q29547588 | ||
| Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks | Q29617463 | ||
| PARP inhibition: PARP1 and beyond | Q29619617 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. | Q30438069 | ||
| Selective estrogen receptor modulators: structure, function, and clinical use. | Q30912456 | ||
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. | Q33161027 | ||
| Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility | Q33231274 | ||
| The molecular portraits of breast tumors are conserved across microarray platforms | Q33241398 | ||
| Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms | Q33244907 | ||
| Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study | Q33386059 | ||
| Steroid hormone receptors in breast cancer management | Q33539154 | ||
| Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. | Q33649918 | ||
| Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer | Q33669053 | ||
| Turnover of BRCA1 involves in radiation-induced apoptosis | Q33789102 | ||
| Triple-negative breast cancer: role of specific chemotherapy agents | Q33900930 | ||
| The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation | Q33911291 | ||
| ??? | Q57134341 | ||
| Similarities and distinctions in the mode of action of different classes of antioestrogens | Q33917000 | ||
| Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer | Q33941574 | ||
| Modulation of the oestrogen receptor: a process with distinct susceptible steps. | Q33955267 | ||
| Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer | Q34058510 | ||
| Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination | Q34146943 | ||
| miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors | Q34157084 | ||
| The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair | Q34203060 | ||
| Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin | Q34204273 | ||
| Estrogen receptor interaction with estrogen response elements | Q34307898 | ||
| Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes | Q34324063 | ||
| Treatment options for patients with triple-negative breast cancer | Q34331406 | ||
| BRCA1 physically associates with p53 and stimulates its transcriptional activity. | Q34467604 | ||
| Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type | Q34546612 | ||
| Concordance among gene-expression-based predictors for breast cancer | Q34555829 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions | Q34727705 | ||
| Evidence for a transcriptional activation function of BRCA1 C-terminal region | Q34736712 | ||
| Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. | Q34742906 | ||
| Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations | Q35051154 | ||
| BRCA1 gene in breast cancer | Q35136087 | ||
| BRCA1 in hormone-responsive cancers | Q35546588 | ||
| The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers | Q35745252 | ||
| Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase | Q35749504 | ||
| BRCA1 in hormonal carcinogenesis: basic and clinical research | Q36261439 | ||
| gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes | Q36418967 | ||
| The role of BRCA1 in transcriptional regulation and cell cycle control | Q36602565 | ||
| BRCA1, a potential predictive biomarker in the treatment of breast cancer | Q36734477 | ||
| Triple-negative breast cancer: therapeutic options | Q36747692 | ||
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. | Q37155629 | ||
| Proteasome-dependent degradation of the human estrogen receptor | Q37160826 | ||
| A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 | ||
| Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial | Q37206289 | ||
| What is triple-negative breast cancer? | Q37325246 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA repair | Q210538 |
| oestrogen receptor | Q416496 | ||
| targeted therapy | Q492646 | ||
| BRCA1 DNA repair associated | Q17487737 | ||
| breast neoplasm | Q23929670 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 14898-14916 | |
| P577 | publication date | 2012-11-14 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer | |
| P478 | volume | 13 |
| Q92878886 | Analysis of the TP53 Deleterious Single Nucleotide Polymorphisms Impact on Estrogen Receptor Alpha-p53 Interaction: A Machine Learning Approach |
| Q35089211 | Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine |
| Q51690290 | Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. |
| Q90740955 | Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers |
| Q37471156 | Polymorphism of UBC9 gene encoding the SUMO-E2-conjugating enzyme and breast cancer risk. |
| Q28602995 | Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusion |
| Q35175999 | Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin |
| Q91738997 | The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments |
Search more.